The Ozempic Society Test

One in eight American adults is now taking a GLP-1 drug. The WHO has issued its first-ever obesity medication guideline. Grocery spending patterns are shifting, fashion sales are surging, and a fierce cultural debate has erupted over whether these drugs represent liberation, a shortcut, a class divide, or all three at once. Everyone has an opinion — but few people have examined which values are actually driving theirs.

The Ozempic Society Test measures your attitudes across six psychologically distinct dimensions: medical progress, personal discipline, equity, body acceptance, systemic thinking, and individual autonomy. Answer the 42 statements honestly, indicating how strongly you agree or disagree with each. There are no right or wrong answers — the test is designed to surface the reasoning beneath your position, not to judge it.

Few medical developments in recent memory have generated as much cultural friction as the GLP-1 receptor agonist class of drugs. Originally developed for type 2 diabetes, medications like semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro, Zepbound) have proven remarkably effective for weight loss — participants in major clinical trials reported in The New England Journal of Medicine lost an average of 14.9% of body weight on semaglutide, and a trial led by Dr. Louis Aronne at Weill Cornell Medicine found tirzepatide produced average weight loss exceeding 25%. By late 2025, the Kaiser Family Foundation reported that 12.4% of U.S. adults were taking a GLP-1 drug, and Gallup documented the first measurable decline in the national obesity rate in over a decade. But the numbers only begin the story. What makes GLP-1 drugs psychologically and culturally fascinating is how they activate deep moral intuitions — about effort, fairness, identity, and what it means to "earn" a body.

Post and Persky¹ demonstrated experimentally that people who lost weight using GLP-1 drugs were judged significantly more negatively than those who achieved the same results through diet and exercise. Participants perceived drug users as "taking a shortcut," and this perception was tied to moral beliefs about effort and willpower — traits that U.S. culture prizes highly. Intriguingly, lean women who used GLP-1 drugs were sometimes judged more harshly than women with obesity who used them, suggesting that the moral calculus is not simply about health need but about perceived deservingness. Barakat et al.² placed these findings within a broader biopsychosocial framework, documenting how rapid pharmacological weight loss can trigger internal conflict, intensify exposure to stigma, and interact with eating disorder risk — particularly when cultural narratives frame treatment as "cheating."

Public discourse tends to flatten the GLP-1 debate into a binary: pro-drug versus anti-drug. But attitudinal analysis reveals at least six distinct psychological orientations, each grounded in different values and concerns. Medical Progress Celebration draws on trust in scientific institutions and a biomedical model of disease. Willpower Moralism reflects deeply held beliefs about effort, character, and the moral significance of self-discipline — beliefs that predate these drugs by centuries. Access and Equity Advocacy centers distributive justice: who benefits, who is excluded, and what that says about a society. Body Acceptance Defense is rooted in the body positivity and Health at Every Size movements, which challenge the premise that thinness equals health. Systemic Root-Cause Thinking takes a public health lens, asking why we are medicating individuals to survive environments we designed. And Personal Autonomy Advocacy prioritizes bodily sovereignty and resists the impulse to moralize other people's medical choices.

These six orientations are not mutually exclusive, but they create revealing tensions. A person can simultaneously celebrate medical progress and worry about equity — recognizing that the drugs work while being troubled by who has access. Someone might value personal autonomy deeply but still feel uncomfortable with systemic root causes being ignored. The test is designed to surface these internal tensions, because they are often where the most interesting self-knowledge lies. Your dominant stance tells you which value you prioritize when they conflict. As Jastreboff and Winfrey³ have argued, shifting from blame to biology requires not just scientific understanding but a cultural reckoning with how we moralize health, weight, and the tools people use to manage both.

Your results are calculated as normed percentile scores across all six dimensions. A percentile score of 75 on Access and Equity Advocacy, for example, means you scored higher than approximately 75% of respondents on that dimension. Your highest-scoring dimension is reported as your dominant stance — the value that most powerfully shapes your opinion on GLP-1 drugs and the broader cultural conversation around weight, health, and personal responsibility. Because the test measures six independent dimensions rather than a single spectrum, most people discover a more nuanced profile than they expected. You may find that your public position ("I support these drugs" or "I'm skeptical") is driven by a very specific underlying value — and that recognizing it changes how you engage with the debate.

Footnotes

1. Post, R. E. & Persky, S. (2024). The effect of GLP-1 receptor agonist use on negative evaluations of women with higher and lower body weight. International Journal of Obesity, 48, 1063–1070. doi:10.1038/s41366-024-01523-5 ↩

2. Barakat, S., et al. (2025). Beyond weight loss: GLP-1 usage and appetite regulation in the context of eating disorders and psychosocial processes. Nutrients, 17(23), 3735. doi:10.3390/nu17233735 ↩

3. Jastreboff, A. M. & Winfrey, O. (2026). Enough: Your Health, Your Weight, and What It's Like to Be Free. Avid Reader Press / Simon & Schuster. ISBN: 978-1668217283 ↩